The French journal of urology最新文献

{"title":"Treatment of interstitial cystitis/bladder pain syndrome: Guidelines from the Committee of Female Urology (CUROPF) of the French Association of Urology (AFU).","authors":"François Meyer, Caroline Brandon, Christian Saussine, Shahed Borojeni, Pierre-Olivier Bosset, Sandrine Campagne-Loiseau, Jean-Nicolas Cornu, Laurence Donon, Lucie Even, Marie Florin, François Hervé, Sophie Hurel, Julia Klap, Marie-Aimée Perrouin-Verbe, Caroline Plassais, Claire Richard, Adrien Vidart, Souhil Lebdai, Amélie Levesque, Caroline Thuillier, Benoît Peyronnet","doi":"10.1016/j.fjurol.2026.103169","DOIUrl":"10.1016/j.fjurol.2026.103169","url":null,"abstract":"<p><p>Interstitial cystitis/bladder pain syndrome (IC/BPS) is a complex chronic condition requiring a multimodal and individualized management approach. This article presents current treatment recommendations for IC/BPS, covering the full therapeutic spectrum from lifestyle and dietary measures to last-resort surgical options. Behavioral interventions, patient education, pelvic floor physical therapy, and psychological support form the cornerstone of first-line management. When these measures prove insufficient, pharmacological treatments - including conventional and atypical analgesics, as well as systemic oral therapies such as pentosan polysulfate sodium - along with intravesical instillations of glycosaminoglycans or dimethyl sulfoxide, may be considered. Interventional techniques, including hydrodistension, intravesical injections of onabotulinumtoxinA, and sacral neuromodulation, represent effective options for refractory patients. Excisional surgery and urinary diversion remain reserved for a carefully selected subgroup of patients presenting with severe, documented bladder-centric disease. Rigorous phenotypic patient selection is the cornerstone of all therapeutic decisions and the principal determinant of prognosis.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103169"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periurethral injection of Bulkamid® for neurogenic vs. non-neurogenic female patients with stress urinary incontinence.","authors":"Mélanie Lepretre, Brice Faurie, Camille Haudebert, Claire Richard, Alexandre Dubois, Amaury Facque, Juliette Hascoet, Benoit Peyronnet","doi":"10.1016/j.fjurol.2026.103097","DOIUrl":"10.1016/j.fjurol.2026.103097","url":null,"abstract":"<p><strong>Introduction: </strong>Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.</p><p><strong>Methods: </strong>From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.</p><p><strong>Results: </strong>Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20 vs. 27%, P=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; P=0.88).</p><p><strong>Conclusion: </strong>Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103097"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported health and quality-of-life after midurethral sling: A comparative analysis from VIGI-MESH registry.","authors":"Xavier Fritel, Léa Mauny, Camille Armengaud, Sandrine Campagne-Loiseau, Sandra Curinier, Laure Panel, Laurent Wagner, Xavier Deffieux, Michel Cosson, Christian Saussine, Renaud de Tayrac, Brigitte Fatton, Grégoire Capon, Emmanuel Chartier-Kastler, Philippe Ferry, Xavier Gamé, Jean-François Hermieu, Sophie Harter, Tristan Gauthier, Géry Lamblin, Emilie Lecornet, Jean-Philippe Lucot, Marie-Aimée Perrouin-Verbe, Rajeev Ramanah, Adrien Vidart, Lucie Merlet, Hocine Drioueche, Arnaud Fauconnier","doi":"10.1016/j.fjurol.2026.103158","DOIUrl":"10.1016/j.fjurol.2026.103158","url":null,"abstract":"<p><strong>Introduction: </strong>Our aim was to evaluate medium-term patient-reported health and quality-of-life after midurethral sling (MUS) insertion and to compare outcomes between retropubic and obturator approaches using data from the French VIGI-MESH registry.</p><p><strong>Material: </strong>In the prospective cohort linked to the registry, 1789 participants who had undergone midurethral sling insertion responded to a health questionnaire that assessed impression of improvement, self-rated health, and quality of life. Self-rated health in our sample was compared to surveys in the French population. A multivariate analysis including an inverse probability of treatment weighting approach was used to balance baseline differences.</p><p><strong>Results: </strong>A total of 1230 participants received a retropubic sling and 559 received an obturator sling placed by 139 surgeons in 27 French centers. Median follow-up was 34 months. Overall, 78.6% of women reported that they were \"much better\" or \"very much better\", and 69.6% reported \"good\" or \"very good\" health (13.5% higher than observed in the general population of the same age). The mean quality of life scale was 76.0/100 (3.8 points higher than observed in the general population of the same age). We were unable to demonstrate a difference in patient-reported outcomes between the retropubic and obturator approaches. After adjustment, serious MUS complications were associated with poorer improvement but not with poorer global self-rated health.</p><p><strong>Conclusion: </strong>In the medium term following MUS insertion, women participating in the VIGI-MESH registry tended to report good self-rated health and quality-of-life. Patient-reported outcomes did not significantly differ between retropubic and obturator approaches.</p><p><strong>Level of evidence: 3: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103158"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of risk factors of early reintervention after prostate laser photovaporization using Greenlight 180 W-XPS.","authors":"Christopher Hakim, Nicolas Hermieu, Nadja Stivalet, Evanguelos Xylinas, Romain Mathieu, Souhil Lebdai, Karim Bensalah, Jean-François Hermieu, Idir Ouzaid","doi":"10.1016/j.fjurol.2026.103165","DOIUrl":"10.1016/j.fjurol.2026.103165","url":null,"abstract":"<p><strong>Introduction: </strong>Greenlight laser prostate photovaporization (PVP) is an alternative treatment for benign prostatic hyperplasia. However, compared to standard techniques such as transurethral resection of the prostate (TURP) and holmium laser prostate enucleation, it has certain limitations with respect to reintervention rates. The aim of our study was to identify the risk factors for reintervention due to recurrent obstruction within 12months following a photovaporization.</p><p><strong>Methods: </strong>This retrospective, multicenter cohort study include patients treated with laser Greenlight 180W-XPS. The primary endpoint was the need for an early reintervention for obstruction. The identified causes for reintervention were: bladder neck sclerosis, urethral stricture, adenoma regrowth, managed by internal urethrotomy, PVP, or TURP.</p><p><strong>Results: </strong>Data of 777 patients were analyzed and 32 reinterventions (4.1%) were recorded within 12months following surgery. Groups were comparable on preoperative data. The predictive factors for reintervention risk were: age (OR 0.92, 95% CI 0.88-0.96), laser usage time (OR 0.10, 95% CI 0.01-0.74), and energy delivered/prostate volume (OR 0.66, 95% CI 0.54-0.80). These factors were associated with a reduced risk of reintervention. The reduction is greater beyond an energy threshold of 4000J/mL (OR 0.10, 95% CI 0.04-0.27).</p><p><strong>Conclusion: </strong>PVP shows a low complication rate. Our results suggest that the energy delivered and the laser emission time are predictive of the quality of treatment. Despite uncertainties regarding this technique, our findings provide urologists with additional confidence in its use and offer predictive factors for assessing treatment's quality.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103165"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic screening of occupational exposures in patients with prostate or kidney cancer.","authors":"Alaric Thibaud, Barbara Charbotel, Philippe Paparel, Alain Ruffion, Céline Lamouroux","doi":"10.1016/j.fjurol.2026.103161","DOIUrl":"10.1016/j.fjurol.2026.103161","url":null,"abstract":"<p><strong>Introduction: </strong>Occupational exposures are recognized risk factors for kidney and prostate cancers. Since 2021-2022 in France, kidney cancers related to trichloroethylene exposure and prostate cancers related to pesticide exposure can be compensated. However, cancers remain largely underreported as occupational diseases. This study aimed to assess a systematic screening of occupational exposures in patients with kidney or prostate cancers and treated at Lyon Sud Hospital (CHLS).</p><p><strong>Methods: </strong>Patients received a self-administered questionnaire to collect their job history and potential occupational exposures to carcinogens. Completed questionnaires were assessed by a physician to determine if an occupational consultation was necessary. If a compensation claim was considered possible by the physician during the consultation, a medical certificate was delivered to the patient.</p><p><strong>Results: </strong>Over three months, 208 patients received the self-administered questionnaire. One hundred and five were returned completed (for 84 prostate cancers and 25 kidney cancers) and a specialized consultation was required for 14 patients. A compensation claim was proposed to 11 patients (10.5%), including eight prostate cancers related to pesticide exposure and three kidney cancers related to trichloroethylene exposure and the need to better inform patients of their rights.</p><p><strong>Conclusion: </strong>Our results show that the implemented screening procedure enabled the identification of patients who could claim their prostate or kidney cancer as an occupational disease, and highlight the importance of a specialized occupational interview.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103161"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continence and quality of life after artificial urinary sphincter implantation in patients with neurological urinary tract disorder: A narrative review over the past 20 years.","authors":"Julia Mistri, Amanda Simon, Marie-Liesse De Guerry, Jérôme Rigaud, Bénédicte Reiss, Chloé Lefevre, Marie-Aimée Perrouin-Verbe","doi":"10.1016/j.fjurol.2026.103151","DOIUrl":"10.1016/j.fjurol.2026.103151","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review assesses two decades of literature about continence and quality of life (QoL) with neurogenic stress urinary incontinence (N-SUI).</p><p><strong>Methods: </strong>We performed a non-systematic literature review using the PubMed Database to identify articles related to continence and quality of life in patients with N-SUI using after artificial urinary sphincter (AUS).</p><p><strong>Results: </strong>Quality of life after AUS in patients with NSUI is rarely assessed in series. In this review, we found 21 series of interest in which only 6 report results on QoL. Most patients achieved social continence (75 to 90%) or total dryness (71 to 75%). Restoring continence provides an important benefit. Among the patients, 78.8% reported to be \"very much improved\". In women, the disappearance of coital incontinence was the most significant factor in improving sexual QoL. A minority reported a deterioration in their sexual life due to the physical presence of the pump. However, AUS in patients N-SUI with is characterized by a significant need for revisions. Urethral erosion and infection are the primary causes for definitive device removal more often with the use of clean intermittent catheterization (CIC), due to urethral trauma. Robot-assisted techniques have further improved safety by reducing perioperative complications and shortening hospital stay.</p><p><strong>Conclusion: </strong>The AUS provides long-term high rates of social continence. QoL and intimacy are under reported in the literature. Future research must prioritize standardized QoL and sexuality questionnaires for neuro-urological populations to report the impact of the implant on these life domains.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103151"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148335504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence thresholds for novel therapeutic strategies in prostate cancer: A consensus statement from the Prostate Cancer Committee of the French Urological Association.","authors":"Michael Baboudjian, Eric Barret, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Jonathan Olivier, Charles Dariane, Romain Mathieu, Arthur Peyrottes, Guilhem Roubaud, Raphaële Renard-Penna, Paul Sargos, Stéphane Supiot, Léa Turpin, Morgan Rouprêt, Guillaume Ploussard","doi":"10.1016/j.fjurol.2026.103162","DOIUrl":"10.1016/j.fjurol.2026.103162","url":null,"abstract":"","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103162"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of tumor size in low-risk upper tract urothelial carcinoma: A multi-institutional analysis.","authors":"Eléonore Petit, Idir Ouzaid, Mathieu Roumiguié, Marco Moschini, Francesco Soria, Jakub Dobruch, David D'Andrea, Cedric Poyet, Romain Mathieu, Mario Alvarez-Maestro, Francesco Montorsi, Wojciech Krajewski, Kees Hendriksen, Luca Afferi, Agostino Mattei, Stefania Zamboni, Claudio Simeone, Atiqullah Azziz, Gregory Verhoest, Shahrokh F Shariat, Benjamin Pradère, Morgan Rouprêt, Evanguelos Xylinas, Pierre-Etienne Gabriel","doi":"10.1016/j.fjurol.2026.103160","DOIUrl":"10.1016/j.fjurol.2026.103160","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prognostic value of tumor size in patients with low-risk upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU).</p><p><strong>Methods: </strong>A retrospective multicenter European analysis was conducted on 3987 patients treated for UTUC at 17 academic institutions. After applying the exclusion criteria, 328 low-risk UTUC patients (pTaN0M0, low grade, unifocal, without hydronephrosis) were included in the analysis. Patients were stratified by tumor size in the RNU specimen: <1cm, 1-1.9cm, and ≥2cm. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated using Kaplan-Meier analysis. Univariable Cox regression analysis was used to evaluate the association between tumor size and disease recurrence. Because other confounding factors intrinsic to the study design were excluded, no multivariable analysis was performed.</p><p><strong>Results: </strong>After a median follow-up of 4.2 [3.9; 4.5] years, 41 (12.5%) patients experienced disease recurrence. Kaplan-Meier analysis showed that tumors ≥2cm were significantly associated with lower RFS compared to tumors of 1-1.9cm and <1cm (81% vs. 95% and 97%, respectively; P<0.05). CSS and OS did not differ significantly among groups (all P>0.05). Univariable Cox regression analysis confirmed that tumor size ≥2cm was a significant predictor of disease recurrence with HR=7.18; 95%CI=[2.94-17.5]; P<0.001.</p><p><strong>Conclusions: </strong>Tumor size ≥2cm is associated with an increased disease recurrence in low-risk UTUC. These findings align with the European Association of Urology guidelines, supporting the inclusion of tumors up to 2cm within the low-risk category.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103160"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of the modified frailty index after radical surgery for upper urinary tract urothelial carcinoma.","authors":"Kays Chaker, Ahmed Chaabouni, Boutheina Mosbahi, Aida Khadhar, Khouloud Ouertani, Ali Chakroun, Afif Limem, Yasmine Laabidi, Wassim Ben Chedly, Yassine Ouanes, Mokhtar Bibi, Mahdi Marrak, Adel Ammous, Ines Chelly, Mourad Hadj Slimene, Yassine Nouira","doi":"10.1016/j.fjurol.2026.103171","DOIUrl":"10.1016/j.fjurol.2026.103171","url":null,"abstract":"<p><strong>Introduction: </strong>Radical nephroureterectomy is the gold standard treatment for non-metastatic upper tract urothelial carcinoma. It is a major surgery associated with significant morbidity, particularly in elderly and frail patients. The modified five-factor frailty index (mFI-5) is a recently used tool to predict postoperative outcomes. This index has been established as a prognostic factor in several cancers. The objective of this study was to evaluate the impact of mFI-5 on the oncological prognosis of patients treated with a Radical Nephroureterectomy for non-metastatic upper tract urothelial carcinoma.</p><p><strong>Patients and methods: </strong>In this multicentric, retrospective, study we collected all patients managed for non-metastatic upper tract urothelial carcinoma who underwent radical nephroureterectomy between 2015 and 2023. The mFI-5 was calculated based on the presence of the following five comorbidities: congestive heart failure within 30 days before surgery, diabetes mellitus, chronic obstructive pulmonary disease, partially or totally dependent functional health status at the time of surgery, and hypertension requiring antihypertensive treatment. Patients were grouped as not frail (mFI-5=0), intermediate (mFI-5=1), and severely frail (mFI-5≥2). Surgical outcomes were evaluated based on perioperative complications and length of hospital stay. Prognostic outcomes included progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>We included 170 patients. From these patients, 47% (n=80) were not frail, 30.58% (n=52) were intermediate, and 22.35% (n=38) were severely frail. Frail patients were more likely to be older (P=0.03), current smokers (P=0.042), and to have chronic kidney disease (P=0.01). Patients with intermediate or severe frailty were more likely to experience postoperative acute kidney injury (P=0.012), thromboembolic event (P=0.003), significant blood loss (P=0.041), and require vasopressor support (P=0.01). Frail patients had a longer hospital length of stay (P<0.001) and unplanned readmission (P=0.02). The 2-year PFS rates were 45% in the severely frail group, 64% in the intermediate group and 87% in the low mFI-5 group, while the corresponding 2-year OS rates were 46%, 78%, and 92% respectively.</p><p><strong>Conclusion: </strong>Frailty, as measured by the mFI-5, is a predictor of postoperative complications, functional decline, and poor oncological prognosis after RNU for UTUC. Its preoperative assessment is crucial for personalized patient management.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103171"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retropubic versus transobturator midurethral slings: Reconsidering the balance between safety and efficacy.","authors":"Renaud de Tayrac","doi":"10.1016/j.fjurol.2026.103099","DOIUrl":"10.1016/j.fjurol.2026.103099","url":null,"abstract":"","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103099"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}